Discovery of Insulin/GLP-1/Glucagon Triagonists for the Treatment of Diabetes and Obesity.
Sign Up to like & getrecommendations! Published in 2022 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.2c00218
Abstract: The combination of insulin and incretin-based therapies has emerged as a potential promising tactic for the treatment of diabetes. Here we report the first example of a unimolecular triagonist to simultaneously target insulin, GLP-1, and… read more here.
Keywords: glp; glp glucagon; chemistry; insulin glp ... See more keywords
Combined Insulin and GLP-1 Receptor Agonists: Simplifying Treatment or Adding Obstacles?
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pharmacy Practice"
DOI: 10.1177/0897190017753041
Abstract: The US Food and Drug Administration recently approved 2 combination products containing a basal insulin and a glucagon-like peptide 1 receptor agonist: insulin glargine/lixisenatide and insulin degludec/liraglutide. These agents were shown to be noninferior in… read more here.
Keywords: insulin; receptor agonists; combined insulin; insulin glp ... See more keywords
Potential Issues with New Basal Insulin/GLP-1 Fixed Combinations: Hydroxyzine-Hydroxyurea Mix-up: Concomitant Use of Entresto and ACE Inhibitors can Lead to Serious Outcomes: More Outpatient Oral Cancer Drugs should be in Blister Packs
Sign Up to like & getrecommendations! Published in 2017 at "Hospital Pharmacy"
DOI: 10.1310/hpj5204-249
Abstract: These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider… read more here.
Keywords: ismp; issues new; insulin glp; new basal ... See more keywords
965-P: Real-World Evidence of the Effect on Glycemic Control with Relatively Simultaneous vs. Sequential Initiation of Basal Insulin and GLP-1 Receptor Agonists
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes"
DOI: 10.2337/db20-965-p
Abstract: Injectable therapy initiation in T2D is often delayed. This retrospective cohort study evaluated the impact of the timing of initiating both basal insulin and GLP-1 RA in people with uncontrolled T2D (HbA1c ≥9 %) on… read more here.
Keywords: pharmaceuticals inc; insulin glp; inc; self ... See more keywords